RESUMEN
UNLABELLED: Neonates with Down's syndrome have an increased risk for congenital leukaemia, particularly acute megakaryoblastic leukaemia (FAB, M7) which most often resolves spontaneously and is called transient leukaemia. It can be observed in non-constitutional trisomy 21 infants then presenting trisomy 21 on blasts cells. OBSERVATION: We report a transient leukaemia with an isolated pericardial effusion in a phenotypically normal neonate. Trisomy 21 was found on blasts cells. Complete remission remains after 32 months. DISCUSSION: Congenital leukaemias, with trisomy 21 on blasts cells have a good prognosis that justifies observation before using chemotherapy.
Asunto(s)
Síndrome de Down/complicaciones , Leucemia Megacarioblástica Aguda/congénito , Antígenos CD/análisis , Síndrome de Down/patología , Humanos , Lactante , Leucemia Megacarioblástica Aguda/patología , Masculino , Remisión EspontáneaRESUMEN
From 1989 to 1998, 341 children were included in the French multicentric LAME (Leucémie Aiguë Myéloblastique Enfant) trials. A total of 309 children were registered in the LAME 89/91 protocol. This intensive regimen included an induction phase (mitoxantrone plus cytarabine), two consolidation courses, one containing timed-sequential high-dose cytarabine, asparaginase and amsacrine; 276 (90%) achieved a CR. The 5-year overall survival (OS) and event-free survival (EFS) were 60+/-4 and 48+/-4%, respectively. From 1997, timed-sequencing of the LAME SP induction chemotherapy led to an unacceptable frequency of consolidation delay; future improvements are unlikely to come from further increases in intensity. The role of allogenic bone-marrow transplantation from an HLA-identical sibling in CR1 was examined. The disease-free survival (DFS) was 52+/-4% for non-allografted patients and 57+/-7% for allografted patients (P=NS); a better OS for allografted patients was shown and could be related either to allo-BMT early in CR1 or to a second allo-BMT in CR2. For the complete responders after consolidation therapy, the 5-year OS was significantly better in patients randomized for no maintenance therapy (MT-) than in patients randomized for MT (77.6+/-8 vs 59+/-8%; P=0.05), while the 5-year DFS was not significantly different. Exposure to low-dose MT might contribute to clinical drug resistance and treatment failure in relapsing patients.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Protocolos Antineoplásicos/normas , Leucemia Mieloide Aguda/terapia , Adolescente , Trasplante de Médula Ósea , Niño , Preescolar , Relación Dosis-Respuesta a Droga , Estudios de Seguimiento , Francia , Humanos , Lactante , Recién Nacido , Leucemia Mieloide Aguda/mortalidad , Inducción de Remisión , Medición de Riesgo , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
PURPOSE: To determine whether the use of a recombinant human granulocyte colony-stimulating factor ([G-CSF] lenogastrim) can increase the chemotherapy dose-intensity (CDI) delivered during consolidation chemotherapy of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Sixty-seven children with very high-risk ALL were randomized (slow early response to therapy, 55 patients; translocation t(9;22) or t(4;11), 12 patients). Consolidation consisted of six courses of chemotherapy; the first, third, and fifth courses were a combination of high-dose cytarabine, etoposide, and dexamethasone (R3), whereas the second, fourth, and sixth courses included vincristine, prednisone, cyclophosphamide, doxorubicin, and methotrexate (COPADM). G-CSF was given after each course, and the next scheduled course was started as soon as neutrophil count was > 1 x 10(9)/L and platelet count was > 100 x 10(9)/L. CDI was calculated using the interval from day 1 of the first course to hematologic recovery after the fifth course (100% CDI = 105-day interval). RESULTS: CDI was significantly increased in the G-CSF group compared with the non-G-CSF group (mean +/- 95% confidence interval, 105 +/- 5% v 91 +/- 4%; P <.001). This higher intensity was a result of shorter post-R3 intervals in the G-CSF group, whereas the post-COPADM intervals were not statistically reduced. After the R3 courses, the number of days with fever and intravenous antibiotics and duration of hospitalization were significantly decreased by G-CSF, whereas reductions observed after COPADM were not statistically significant. Duration of granulocytopenia was reduced in the G-CSF group, but thrombocytopenia was prolonged, and the number of platelet transfusions was increased. Finally, the 3-year probability of event-free survival was not different between the two groups. CONCLUSION: G-CSF can increase CDI in high-risk childhood ALL. Its effects depend on the chemotherapy regimen given before G-CSF administration. In our study, a higher CDI did not improve disease control.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Neutropenia/inducido químicamente , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Trombocitopenia/inducido químicamente , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Niño , Preescolar , Ciclofosfamida/administración & dosificación , Citarabina/administración & dosificación , Dexametasona/administración & dosificación , Relación Dosis-Respuesta a Droga , Doxorrubicina/administración & dosificación , Etopósido/administración & dosificación , Femenino , Factor Estimulante de Colonias de Granulocitos/farmacología , Humanos , Lactante , Recién Nacido , Masculino , Metotrexato/administración & dosificación , Neutropenia/prevención & control , Prednisona/administración & dosificación , Proteínas Recombinantes , Trombocitopenia/prevención & control , Resultado del Tratamiento , Vincristina/administración & dosificaciónAsunto(s)
Histiocitosis de Células de Langerhans/diagnóstico por imagen , Adolescente , Antígenos CD1 , Líquido del Lavado Bronquioalveolar/citología , Diagnóstico Diferencial , Humanos , Células de Langerhans/patología , Macrófagos/patología , Masculino , Radiografía Torácica , Tomografía Computarizada por Rayos XRESUMEN
Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) appears effective and relatively safe for the treatment of bleeding and for surgical prophylaxis in patients with Glanzmann thrombasthenia as reported to the International Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the Registry data is the heterogeneity of treatment protocol, including dosage, number of doses used, duration of treatment before declaration of failure, and mode of rFVIIa administration (bolus v continuous infusion). The data are not yet sufficient to define optimal regimens for various indications such as the type of bleeding or the type of procedures. The place of this drug compared to platelet transfusion in the overall management of patients with Glanzmann thrombasthenia will need to be determined in relationship to a number of challenges and unresolved issues in the clinical care of these patients. These issues include: how to improve local measures for patients with mucosal bleeds, optimal management of young women during menarche, optimal platelet transfusion regimens for various indications, the relationship between antiplatelet antibodies detected by monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and effectiveness of platelet transfusion, whether there are other biological tests that may correlate with effectiveness of platelet transfusion, and management of pregnancy and delivery regarding antiplatelet immunization.
Asunto(s)
Factor VII/uso terapéutico , Proteínas Recombinantes/uso terapéutico , Trombastenia/tratamiento farmacológico , Coagulantes/uso terapéutico , Factor VIIa , Femenino , Humanos , Masculino , Transfusión de Plaquetas/efectos adversos , Embarazo , Complicaciones Hematológicas del Embarazo/tratamiento farmacológico , Complicaciones Hematológicas del Embarazo/terapia , Trombastenia/diagnóstico , Trombastenia/terapiaRESUMEN
PURPOSE: Prospective report of Endobulin clinical tolerance experience for 19 months over a large number of patients. METHOD: Collect diagnosis, age, gender, weight, dose regimen, infusion duration, and clinical tolerance of Endobulin. Treatment with this product was the only inclusion criteria in this follow-up. RESULTS: A hundred and forty-two patients, 85 children and 57 adults, mean age 23 (1-85 years) received 70 substitutive treatments for primary immunodeficiency, 36 substitutive treatments for secondary immunodeficiency and 36 immunomodulatory treatments. A thousand six hundred and sixty Endobulin infusions that led to 14, 061.5 g, from 52 different batches. Tolerance was judged as good for 135 patients even though side effects occurred in 2 of them. Thus, 133 out of 142 patients, that is 93.7% did not present any side effect and their tolerance to Endobulin infusions was defined as good. Tolerance was bad for 7 patients because of side effects occurrence. For a mean number of 11.7 infusions per patient (1-31), the 9 side effects observed led to a rate of 0.54% of collected infusions and 6.3% of patients included. CONCLUSION: This therapeutic follow-up of 142 patients confirms Endobulin clinical tolerance judged as good in 93.7% of patients (133/142) with a very low rate of side effects of 0.54% of infusions (9 side effects for 1660 infusions) for a mean number of 11.7 infusions per patient for an average of 10.9 months follow-up.
Asunto(s)
Enfermedades del Sistema Inmune/tratamiento farmacológico , Inmunoglobulinas Intravenosas/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Lactante , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Resultado del TratamientoRESUMEN
Inflammatory pseudo-tumor of the liver (IPT) are benign encapsulated masses. IPT or inflammatory myofibroblastic tumor is a myofibroblastic proliferation with chronic inflammatory cell infiltration of unknown origin. A four-year-old girl, with cutaneous flushing of the face and biological inflammatory syndrome was referred for abdominal investigation. Ultrasound examination showed a 5-cm mass located in the anterior segment of the right hepatic lobe. After abdominal CT showing slightly vascular feature of this right hepatic mass, diagnosis was made through percutaneous US-guided fine needle biopsy. Surgical resection was performed and pathologic examination of the mass confirmed preoperative diagnosis. Clinical outcome was good.
Asunto(s)
Granuloma de Células Plasmáticas/diagnóstico , Hepatopatías/diagnóstico , Biopsia , Preescolar , Femenino , Granuloma de Células Plasmáticas/diagnóstico por imagen , Granuloma de Células Plasmáticas/patología , Humanos , Hígado/patología , Hepatopatías/diagnóstico por imagen , Hepatopatías/patología , Imagen por Resonancia Magnética , Tomografía Computarizada por Rayos X , UltrasonografíaRESUMEN
The value of thyroid cell cultures in vitro has been demonstrated in auto-immune thyroiditis in animals. We have used the same method in man to investigate for serum thyroid-stimulating antibodies (TSAb) by measuring cyclic AMP production in thyroid cell cultures incubated with immunoglobulins from patients with Graves' disease. The specificity of the reaction is strictly directed either against TSH or against immunoglobulins from patients with Graves' disease; 92% of the sera of our untreated Graves' disease patients were positive. The value of this technique compared to the other methods used for detecting TSAb is discussed.
Asunto(s)
Autoanticuerpos/análisis , Enfermedad de Graves/inmunología , Glándula Tiroides/inmunología , Adolescente , Adulto , Anciano , Células Cultivadas , Niño , Preescolar , AMP Cíclico/metabolismo , Femenino , Humanos , Inmunoglobulina G/farmacología , Lactante , Masculino , Persona de Mediana Edad , Tirotropina/farmacología , Factores de TiempoRESUMEN
UNLABELLED: The aim of this study was to show that steroid therapy taken before the diagnosis of acute lymphoblastic leukemia (ALL) can alter the management of the disease. PATIENTS AND METHODS: We conducted a multicenter retrospective study on 11 children treated between 2005 and 2011, who received oral steroids ranging from 0.6 to 3.3mg/kg/day prednisolone equivalent for a duration of 2 to 15 days during the 2 months prior to diagnosis of ALL. RESULTS: Four children had febrile pancytopenia. Among them, 2 had severe infections and a noncontributive bone marrow aspiration. One of them presented a severe tumoral lysis syndrome and was hospitalized twice in the intensive care unit. Two teenagers had central nervous system involvement at diagnosis of T-ALL, 1 having associated cutaneous locations, the second one showing pulmonary and central nervous system (CNS) leukostasis with renal failure and disseminated intravascular coagulation. One child died of septic shock during the induction phase of steroid-resistant T-ALL. Four children had no complications during the induction phase. Steroid resistance occurred in 5 cases and steroid sensitivity could not be evaluated in 3 cases. Three allogeneic bone marrow transplants were performed: the first one because of early CNS relapse, the 2 others because of initial treatment resistance. CONCLUSION: Steroids can induce a delay in the management of ALL and seem to favor initial complications, and possibly increase diffuse locations as well as steroid resistance. Their prescription needs to be carefully managed, especially for uncharacteristic infectious symptoms. Then a complete blood count should be done.
Asunto(s)
Glucocorticoides/efectos adversos , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Prednisolona/efectos adversos , Adolescente , Niño , Preescolar , Femenino , Glucocorticoides/uso terapéutico , Humanos , Lactante , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Prednisolona/uso terapéutico , Estudios RetrospectivosRESUMEN
UNLABELLED: Discovering chronic illnesses in children initially shatters the family balance and triggers emotional reactions. PATIENTS AND METHODS: We retrospectively report parents' experiences and emotional reactions to learning the diagnosis of hemophilia in their children. Twenty-six parents (18 mothers, 8 fathers) of 24 hemophiliac A or B children (major n=8, moderate n=6, mild n=10), aged from 0 to 18 years, were individually asked to answer a separate questionnaire for each child during a systematic consultation. We obtained 29 completed questionnaires. RESULTS: The diagnostic circumstances were a major bleeding episode (n=8), frequent hematomas (n=4), preoperative blood sample (n=4), and familial screening (n=8). In 9 cases, both parents were informed of the diagnosis at the same time and in 13 cases, the mother was alone. The most frequent feelings were future apprehension (n=20), initial shock reaction (n=18), anxiety (n=12), and guilt (n=10) expressed by mothers only. Parents' emotional states were neither correlated with the severity of the disease nor with the diagnostic circumstances. All parents questioned reported being satisfied with the quality of the initial information. CONCLUSION: The crisis generated by learning the diagnosis of a chronic disease in their children warrants delivering initial information to both parents at the same time, especially in hemophilia since mothers tend to be more concerned.
Asunto(s)
Hemofilia A , Padres/psicología , Adolescente , Adulto , Niño , Preescolar , Femenino , Hemofilia A/diagnóstico , Humanos , Lactante , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Encuestas y Cuestionarios , Adulto JovenRESUMEN
BACKGROUND: The development of an inhibitor is the major complication facing patients with hemophilia A treated by administration of factor (F) VIII concentrates. Restoration of tolerance to FVIII can be achieved by prolonged administration of FVIII (immune tolerance induction, ITI). Although ITI has been used for more than 30years in patients with hemophilia A and inhibitor, its mechanism of action is still poorly understood. OBJECTIVES: As administration of high doses of antigen can induce the apoptosis of the T cells recognizing the antigen, a potential mechanism of action of ITI may be the deletion of FVIII-specific T cells. PATIENTS/METHODS: We studied the CD4+ T-cell response to FVIII in five (one mild, one moderate and three severe) patients successfully desensitized by administration of FVIII and in control subjects. RESULTS: Following repeated stimulation with autologous dendritic cells loaded with FVIII, FVIII-specific T oligoclonal cell lines were expanded from the blood of one of the successfully desensitized patients. The FVIII-specific T cells produced IL-5, IL-13 and IL-2. By contrast, FVIII-specific T-cell lines could not be derived from three patients with mild hemophilia A without inhibitor or from four normal control subjects. CONCLUSIONS: These data represent the first analysis of the cellular mechanisms regulating the induction of tolerance to FVIII. They demonstrate that successful tolerance induction may occur without deletion of FVIII-specific T cells.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Factor VIII/administración & dosificación , Hemofilia A/complicaciones , Tolerancia Inmunológica/inmunología , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/metabolismo , Técnicas de Cultivo de Célula , Células Dendríticas/inmunología , Relación Dosis-Respuesta a Droga , Factor VIII/efectos adversos , Factor VIII/inmunología , Hemofilia A/tratamiento farmacológico , Hemofilia A/inmunología , Humanos , Interleucinas/biosíntesis , Especificidad del Receptor de Antígeno de Linfocitos TAsunto(s)
Histiocitosis/patología , Paniculitis/patología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Médula Ósea/patología , Niño , Ciclofosfamida/administración & dosificación , Diagnóstico Diferencial , Doxorrubicina/administración & dosificación , Humanos , Hipoproteinemia/complicaciones , Leucopenia/complicaciones , Masculino , Paniculitis/complicaciones , Paniculitis/tratamiento farmacológico , Prednisona/administración & dosificación , Neoplasias Cutáneas/patología , Esplenomegalia , Vincristina/administración & dosificaciónAsunto(s)
Deficiencia del Factor XIII/terapia , Fibrinolisina/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Factor XIII , Deficiencia del Factor XIII/congénito , Femenino , Fibrinolíticos , Humanos , Lactante , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
BACKGROUND: A secondary end point of the NBL90 protocol (Rubie H et al. Pediatr Oncol 2001;36:247-250) was the concern in this infant population for possible carboplatin-(CBDCA) induced late side effects including impaired renal and hearing functions. PROCEDURE: Glomerular filtration rate (GFR), tubular function (TF), pure tone audiometry (PTA), high-frequency, and transient evoked-otoacoustic emission were prospectively assessed in 30 children alive and disease-free 6 years after the end of the treatment. RESULTS: Median age at diagnosis and at assessment was 4.7 months and 7 years, respectively. Blood pressure was < or =97.5 centile in all children. The mean estimated GFR was 114 +/- 13 ml/min/1.73 m(2) by Schwartz formula [range 87-145]. TF assessment failed to demonstrate any impairment. 29/30 children had grade 0 ototoxicity and all transient evoked otoacoustic emission were normal. CONCLUSIONS: With a 6-year follow-up the combination of VP16 and carboplatin given at conventional doses is safe on renal and hearing functions in infants with unresectable neuroblastomas treated according to SFOP NB90.
Asunto(s)
Antineoplásicos/efectos adversos , Carboplatino/efectos adversos , Pérdida Auditiva/inducido químicamente , Enfermedades Renales/inducido químicamente , Neuroblastoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica , Femenino , Francia/epidemiología , Pérdida Auditiva/epidemiología , Humanos , Lactante , Recién Nacido , Enfermedades Renales/epidemiología , MasculinoRESUMEN
Lymphocytes from freshly diagnosed untreated GD patients can be induced to produce in-vitro IgG, and more precisely TSI in the presence of PWM, a T cell dependent polyclonal activator of B cells. TSI were measured from days 8 to 41 of culture, using a functional cAMP production assay, after the deposition of culture supernatants on HTEC. Spontaneous or PWM induced IgG synthesis was optimal on day 28 of culture for GD MNC, with amounts of IgG in PWM stimulated GD culture supernatants twice those found in unstimulated GD MNC. Moreover only PWM stimulated GD MNC produce IgG which induce cAMP production by cultured HTEC, with a significant correlation between in-vitro IgG and cAMP levels.
Asunto(s)
Linfocitos B/inmunología , Enfermedad de Graves/inmunología , Inmunoglobulina G/biosíntesis , Activación de Linfocitos , Adulto , Bioensayo , Carbimazol/farmacología , AMP Cíclico/biosíntesis , Femenino , Humanos , Inmunoglobulinas Estimulantes de la Tiroides , Masculino , Persona de Mediana Edad , Mitógenos de Phytolacca americana/farmacología , Glándula Tiroides/metabolismoRESUMEN
Following the occurrence in two siblings of parvovirus B19-related acute transient erythroblastopenia with specific IgMs, hereditary spherocytosis (HS) was diagnosed for the first time in the two patients as well as in three other members of the family.
Asunto(s)
Infecciones por Parvoviridae/complicaciones , Aplasia Pura de Células Rojas/etiología , Esferocitosis Hereditaria/complicaciones , Preescolar , Salud de la Familia , Femenino , Humanos , Masculino , Linaje , Esferocitosis Hereditaria/genéticaRESUMEN
Hereditary spherocytosis and beta thalassaemia are rarely inherited together. We have studied a large family of Caucasian extraction in whom these two diseases segregate independently over four generations. The diagnosis rested on specialized laboratory findings and in a number of subjects on the measurement of alpha and beta globin chain synthesis. In addition, a viscometric method (osmotic gradient ektacytometry) was used to evaluate the rheological function of the erythrocytes. In patients inheriting both diseases, the results indicate that the clinical and biological expression of hereditary spherocytosis is modulated by the degree of imbalanced globin chain synthesis. The opposite properties of spherocytes (decreased surface/volume ratio, increased haemoglobin concentration) and thalassaemic red cells (increased surface/volume ratio, decreased haemoglobin concentration) may explain the antagonistic influence of each genotype.
Asunto(s)
Familia , Globinas/biosíntesis , Esferocitosis Hereditaria/genética , Talasemia/genética , Adolescente , Adulto , Viscosidad Sanguínea , Niño , Femenino , Humanos , Masculino , Linaje , Esferocitosis Hereditaria/sangre , Talasemia/sangreRESUMEN
A case of congenital embryonal rhabdomyosarcoma of the right shoulder is described. The patient was the first child born to a 24 year-old woman who had previously been treated for sterility. The diagnosis was made by echography during the 36th week of gestation. This full term white boy was born by cesarean section because of the tumor size. Surgical treatment was completed by chemotherapy. Despite 4 courses of VAC, local recurrence was noted that led to a second surgical excision followed by a new cyclic chemotherapy (IVA). The treatment was fairly well tolerated. The child is well 24 months later.
Asunto(s)
Enfermedades Fetales/diagnóstico , Diagnóstico Prenatal , Rabdomiosarcoma/diagnóstico , Neoplasias de los Tejidos Blandos/diagnóstico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Ciclofosfamida/administración & dosificación , Dactinomicina/administración & dosificación , Femenino , Humanos , Ifosfamida/administración & dosificación , Recién Nacido , Masculino , Recurrencia Local de Neoplasia , Embarazo , Tercer Trimestre del Embarazo , Rabdomiosarcoma/congénito , Rabdomiosarcoma/embriología , Rabdomiosarcoma/terapia , Hombro , Neoplasias de los Tejidos Blandos/congénito , Neoplasias de los Tejidos Blandos/embriología , Neoplasias de los Tejidos Blandos/terapia , Ultrasonografía , Vincristina/administración & dosificaciónRESUMEN
A 10-year-old boy with leukaemia-associated hypercalcaemia was treated with aminohydroxypropylidene biphosphonate (AHPrBP previously APD) in a total dosage of 60 mg over 5 days, when the condition failed to respond to rehydration and frusemide and no sustained effect was produced by haemodialysis with a calcium (Ca)-free dialysate. Bone films showed no lytic lesions, and AHPrBP, which is a potent inhibitor of osteoclast-mediated bone resorption was well tolerated and induced a rapid and sustained fall in plasma Ca (from 3.42 to 2.07 mM in 5 days). Plasma magnesium and alkaline phosphatase remained normal. The results could have been affected by other drugs [vincristine, cyclophosphamide, zorubicin (Rubidazone) L-asparaginase and prednisone] which were simultaneously administered. However, the observation that: (1) the response curve of plasma Ca was similar to that reported when AHPrBP was used alone, (2) there was complete inhibition of urinary Ca excretion and (3) hypocalcaemia occurred suggests that AHPrBP was the major cause of the reduction in plasma Ca. AHPrBP should be considered a potential therapy for hypercalcaemia in childhood malignancy.